TF
ADMA icon

Trek Financial’s ADMA Biologics ADMA Stock Holding History

Trek Financial’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-123,629
Closed -$2.47M – 407
2024
Q3 		$2.47M Buy
+123,629
New +$1.92M 0.18% 127

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Trek Financial's ADMA Position: Q4 2024 in Review

Trek Financial sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 123,629 shares — an estimated $2.47M sold.

Trek Financial first reported a position in ADMA in Q3 2024 and held it in 1 quarter. The position peaked at $2.47M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Trek Financial reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Trek Financial sold 123,629 ADMA Biologics shares in Q4 2024, an estimated $2.47M.
  • Trek Financial first reported a position in ADMA Biologics in Q3 2024 and held it in 1 quarter.
  • Trek Financial's ADMA Biologics position peaked at $2.47M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Trek Financial's 13F filing for Q4 2024, filed 13 Feb 2025.